Case-Based Peer Perspectives: A 64-Year-Old Male with Lung Cancer

Expert oncologist Jason Porter, MD, centers discussion on a patient case of non–small cell lung cancer and highlights novel treatment modalities in this setting.

EP. 1: Patient Case: A 64-Year-Old Man With Metastatic Squamous Cell NSCLC

December 19th 2022

Centering discussion on a patient scenario of metastatic squamous cell NSCLC, expert oncologist Jason Porter, MD, shares his initial impressions on the case.

EP. 2: First-Line Treatment Options for Metastatic Squamous Cell NSCLC

December 19th 2022

Comprehensive insight on the first-line treatment armamentarium available to patients diagnosed with metastatic squamous cell non–small cell lung cancer.

EP. 3: EMPOWER-Lung3: Cemiplimab Combination Therapy in Non–Small Cell Lung Cancer

December 19th 2022

Expert perspective on the EMPOWER-Lung3 clinical trial, which combined cemiplimab with chemotherapy as frontline treatment for patients with advanced NSCLC.

EP. 4: NSCLC: Optimizing Management of Adverse Events Seen on EMPOWER-Lung3

December 19th 2022

Jason Porter, MD, shares a brief review of the toxicity profile noted on EMPOWER-Lung3 and provides practical advice on how to monitor for and manage adverse events.

EP. 5: Real-World Selection and Use of IO Therapy in Metastatic NSCLC

December 19th 2022

In light of clinical data and real-world experience, Jason Porter, MD, considers how he would best select patients with non–small cell lung cancer for IO therapy.

EP. 6: Metastatic NSCLC: Unmet Needs and Future Directions in Care

December 19th 2022

Closing out his discussion on the management of advanced non–small cell lung cancer, an expert oncologist provides his hopes for future evolutions in the treatment paradigm.